SAGA Diagnostics
3 known investors
SAGA Diagnostics develops Pathlight, a blood-based, tumor-informed multi-cancer test for detecting molecular residual disease (MRD) using whole-genome sequencing and personalized multiplex digital PCR assays to track circulating tumor DNA. It serves clinicians and biopharma companies, with its first commercial indication for early-stage breast cancer patients in the U.S.
AI & Machine LearningBiotechDigital Health
Investors · 3
Frequently asked questions
- What does SAGA Diagnostics do?
- SAGA Diagnostics develops Pathlight, a blood-based, tumor-informed multi-cancer test for detecting molecular residual disease (MRD) using whole-genome sequencing and personalized multiplex digital PCR assays to track circulating tumor DNA. It serves clinicians and biopharma companies, with its first commercial indication for early-stage breast cancer patients in the U.S.
- Who are SAGA Diagnostics's investors?
- SAGA Diagnostics's investors include FSG, Hadean Ventures, LU Innovation.